Urinary Incontinence Devices Market worth $7.97 billion by 2030 | Business Trends and Outlook

The global urinary incontinence devices market, valued at US$3.82 billion in 2023, stood at US$4.22 billion in 2024 and is projected to advance at a resilient CAGR of 11.2% from 2025 to 2030, culminating in a forecasted valuation of US$7.97 billion by the end of the period. As aging is a major risk factor for urinary incontinence, countries with a growing elderly population are witnessing a higher demand for effective incontinence management solutions. Moreover, the rising occurrence of disorders like overactive bladder, neurogenic bladder, and post-operative urinary incontinence is further accelerating the market growth. Technological improvements in urinary incontinence treatments & devices, improving healthcare infrastructure, and the growing expenditure on healthcare are increasing the accessibility and adoption.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62500756

By Based on product type, the urinary incontinence devices market is segmented into urinary catheters, vaginal & urethral slings, electrical stimulation devices, artificial urinary sphincters, and other urinary incontinence devices. Among these, in 2023, the urinary catheters segment accounts for the highest share in the urinary incontinence devices market and is projected to grow at the fastest rate during forecast period. This segment is further divided into intermittent catheters, indwelling catheters, and external catheters. Among these intermittent catheters to hold the largest market share in 2023. As per data from UroToday, intermittent catheterization (IC) is considered the gold standard for individuals with bladder dysfunction due to neurologic or non-neurologic causes - a significant and growing population in the US. With an increase in neurologic diseases, the use of intermittent catheters is anticipated to increase during the forecast period.

By End User, the urinary incontinence devices market is segmented into hospitals, physician offices, and other end users. Among these hospitals are holding the largest share in urinary incontinence devices market in 2023. The hospital segment includes all hospitals (large, small, and medium-sized) that treat or manage patients with urinary incontinence. In hospitals, urinary incontinence products, especially urinary catheters, are widely used in patients that have been administered anesthesia or have developed incontinence after surgery. The significant share of this end-user segment can be attributed to the large volume of patients visiting hospitals for surgical treatment, and the high incidence of chronic diseases such as urinary incontinence, multiple sclerosis, and spina bifida.

By geography, the urinary incontinence devices market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa. The Europe accounted for the largest share of the urinary incontinence devices market in 2023. The urinary incontinence devices market in Europe is mature, particularly in Germany and the UK. The increasing aging population and rising demand for adult incontinence care products are expected to drive the urinary incontinence devices market in Europe. According to the WHO, by 2025, Europe will account for approximately 119 million people aged 65 and above, about 16% of the total population in the region. The increasing geriatric population will generate the need for urinary incontinence devices such as urinary catheters, vaginal & urethral slings, artificial urinary sphincters, electrical stimulation devices, etc. to support the market growth in this region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=62500756

Europe dominates the global urinary incontinence devices market in 2023.

The urinary incontinence devices market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa. The Europe accounts for the largest market share of XX% in the urinary incontinence devices market in 2023. The urinary incontinence devices market in Europe is mature, particularly in Germany and the UK. The increasing aging population and rising demand for adult incontinence care products are expected to drive the urinary incontinence devices market in Europe. According to the WHO, by 2025, Europe will account for approximately 119 million people aged 65 and above, about 16% of the total population in the region. Th increasing geriatric population will generate the need for urinary incontinence devices such as urinary catheters, vaginal & urethral slings, artificial urinary sphincters, electrical stimulation devices, etc. to support the market growth in this region.

Key Players

Prominent players in the urinary incontinence devices market include, Coloplast Corp (Denmark), B. Braun SE (Germany), Johnson & Johnson Services, Inc. (US), Convatec Inc. (UK), Boston Scientific Corporation (US), Hollister Incorporated (US), Becton, Dickinson and Company (BD) (US), Cook Group (US), Cardinal Health (US), Laborie (US), Medtronic (Ireland), and Teleflex Incorporated (US).

B. BRAUN SE (GERMANY)

B. Braun SE: The Second Most Significant Player in the Urinary Incontinence Devices Market in 2023. B. Braun has diversified and comprehensive medical products, allowing it to serve a wide range of healthcare needs. B. Braun operates in more than 64 countries, making it one of the leading medical device manufacturers, providing excellent market penetration and servicing both developed and emerging markets. It has increased its presence in emerging markets, especially in Asia, Latin America, and the Middle East, where demand for healthcare products and services is growing quickly.

JOHNSON & JOHNSON SERVICES, INC. (US):

Johnson & Johnson Services, Inc. is recognized as the third leading player in the urinary incontinence devices market in 2023. The company has a major market presence in more than 60 countries in various regions, including North America, Europe, the Asia Pacific, and Africa. It has more than 265 operating companies and runs its businesses through its main subsidiaries. Investments at the levels that J&J makes over years guarantee a constant stream of innovation within the medical devices, pharmaceuticals, and biotechnology industries. These initiatives not only streamline its market approach but also ensure that it addresses landscape shifts in patient care with advanced technologies and innovative products.

Enquire Buying Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=62500756